An Exposed Domain in the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Induces Neutralizing Antibodies

Tong Zhou,1 Hong Wang,1 Danlin Luo,2 Thomas Rowe,3 Zheng Wang,1 Robert J. Hogan,3 Shihong Qiu,2 Robert J. Bunzel,2 Guoqiang Huang,2 Vinod Mishra,4 Thomas G. Voss,3 Robert Kimberly,1 and Ming Luo2*

Division of Clinical Immunology and Rheumatology, Department of Medicine,1 and Department of Microbiology,2 University of Alabama at Birmingham, Birmingham, Alabama 35294; Division of Homeland Security and Emerging Infectious Diseases Research, Southern Research Institute, Birmingham, Alabama 35205-5305; and Southern Biotechnology Associates, Birmingham, Alabama 35209

Received 12 November 2003/Accepted 19 February 2004

Exposed epitopes of the spike protein may be recognized by neutralizing antibodies against severe acute respiratory syndrome (SARS) coronavirus (CoV). A protein fragment (S-II) containing predicted epitopes of the spike protein was expressed in Escherichia coli. The properly refolded protein fragment specifically bound to the surface of Vero cells. Monoclonal antibodies raised against this fragment recognized the native spike protein of SARS CoV in both monomeric and trimeric forms. These monoclonal antibodies were capable of blocking S-II attachment to Vero cells and exhibited in vitro antiviral activity. These neutralizing antibodies mapped to epitopes in two peptides, each comprising 20 amino acids. Thus, this region of the spike protein might be a target for generation of therapeutic neutralizing antibodies against SARS CoV and for vaccine development to elicit protective humoral immunity.

The genome sequence of severe acute respiratory syndrome (SARS) coronavirus (CoV) provided direct evidence that a new CoV is responsible for the recent SARS epidemic in Asia and Canada (11, 15). This new CoV appears to have host specificities different from those of previously known CoVs. One of the potential cell tropism determinants is the spike (S) protein that recognizes the host receptor (2, 4, 21). The genome sequence of the SARS CoV predicts an S protein of 1,255 amino acids (aa) (GenBank accession no. 29836496) with 23 potential N-linked glycosylation sites (11, 15), and the N terminus of the S protein contains a signal peptide that is presumably removed in the mature virion (11, 15). Unlike some CoVs, such as human CoV (HCoV) 229E, in which the S protein is cleaved into S1 and S2 subunits, the S protein in SARS CoV is not cleaved. Alignment of the SARS CoV S protein with the S proteins of other CoVs, including HCoV 229E, showed low homology. However, the SARS CoV S protein could be aligned in the S2 region with higher homology than with the S1 region. S2 contains the membrane-anchoring and fusion region, which plays a key role in virus assembly and entry (8). Despite the lack of significant homology with the S1 protein of HCoV 229E, transmissible gastroenteritis virus (TGEV), or mouse hepatitis virus (MHV), which contains the receptor binding site (1, 3, 10, 16), it is likely that the receptor binding site of the SARS CoV S protein is located in the N-terminal part corresponding to the S1 region.

The host receptor for group I CoVs, such as HCoV 229E and TGEV, is aminopeptidase N (also known as CD13) (4, 21). MHV, a group II CoV (5, 6), recognizes carcinoembryonic antigen-related cell adhesion molecules as another group of CoV receptors. Viral entry is initiated by attachment of the S protein to the specific host receptor, which triggers a conformational change in the S protein. This receptor-induced conformational change exposes the fusogenic region embedded in the S2 region that inserts into the cellular membrane (12, 22). In HCoV 229E, the receptor binding domain has been narrowed to a region comprising residues 407 to 547 in S1. Protein fragments with these residues retain the ability to bind the host receptor, aminopeptidase N, and are recognized by monoclonal antibody (MAb) 4-9H.5 (1). Similar results were obtained for TGEV, where the receptor binding domain is located between residues 506 and 655 (7, 18). Neutralizing determinants are also located in this region. The receptor binding domain of MHV also maps to the N-terminal end (330 aa) of the S protein (10). The definitive region that binds the host receptor has not been clearly mapped on the S protein of SARS CoV.

In this report, we describe a protein fragment of the SARS CoV S protein (residues 485 to 625). When this fragment is produced as a refolded recombinant protein from E. coli, it attaches specifically to the surface of Vero E6 cells. The MAbs against this fragment recognize the native S protein in SARS CoV and exhibit neutralizing activity against SARS CoV infection in cell culture. Thus, this region of the S protein may be related to receptor recognition and contains neutralizing epitopes of the SARS CoV S protein.

MATERIALS AND METHODS

Expression of S fragments. Nineteen oligonucleotides of both sense and antisense sequences were synthesized (IDT, Coralville, Iowa) for the S-II fragment (aa 485 to 625). Four picomoles of each oligonucleotide was mixed in 1× PCR buffer and incubated with 2.5 U of Taq polymerase in a final volume of 50 μl at 72°C for 20 min. Five microliters of the annealed and ligated product was used as a template for a PCR with 5′ and 3′ primers for 30 cycles. The 438-bp PCR product was purified and cloned into the pET100/D/TOPO expression vector.
### A

<table>
<thead>
<tr>
<th>SCORE</th>
<th>LENGTH</th>
<th>REGION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.214</td>
<td>25</td>
<td>490-514</td>
</tr>
<tr>
<td>1.183</td>
<td>15</td>
<td>345-359</td>
</tr>
<tr>
<td>1.168</td>
<td>8</td>
<td>4-11</td>
</tr>
<tr>
<td>1.160</td>
<td>31</td>
<td>591-621</td>
</tr>
<tr>
<td>1.155</td>
<td>19</td>
<td>374-392</td>
</tr>
</tbody>
</table>

### B

503 LNA PATVC GPK LSTD LK NQCVNF NGLTG VLVPS SSTSF RQPQ PQQF G RD VSD F DSV 562
+ P VG ++ ++C +N ++G GV + S + F ++
425 ITGPQP VGSSPF MNVT LDKCT KNYI YD VS GVR VS N ------------ DTF LNGI 471
563 RD PKTS EIL D SP CAFGS V SITP GTA S EVA V AL YQD VNC T DVSTA IHAD QLTP AWR 621
TS +L G + ITP N ++ V Q A + L +
472 TYTSTSG N LGF DK V TGTI YSIT P - CNPP DQLLV YQ Q ------------ AVVG AML SEN FT 521

622 YSTGNV ----PQT A G CLI GA EHV DTS YECD I PI ----GAGIC A SYHT V SLL RST SQK 672
Y NV F +Y C + G+CA +++ Q
522 YGFSNVVELPKFF YAS NG ------------ TYN C TD A VLY S P G V C ADG SIIA V ----QP 566

### C

- [Image of a gel electrophoresis](https://jvi.asm.org/)

### D

- [Graph showing S-RBD](https://jvi.asm.org/)

### E

- [Bar graph showing MFI](https://jvi.asm.org/)

### F

- [Histograms showing](https://jvi.asm.org/) S1 (aa145-480) and S3 (aa601-973)
Flow cytometry analysis of the binding activity of S fragments. The purified, refolded recombinant protein fragments were dialyzed against phosphate-buffered saline (PBS), and then 2 mg of protein per ml was conjugated with LC- Biotin (Pierce) at a 1:25 protein/biotin molar ratio according to the manufacturer’s instructions. After conjugation, free biotin was removed by dialysis. For flow cytometry analysis, 106 Vero E6 cells (American Type Culture Collection) were incubated with the diluted biotinylated S-II or control protein in 20 ml of fluorescence-activated cell sorter (FACS) buffer (5% fetal calf serum, 0.01% NaN3, in PBS) at room temperature (RT) for 30 min. After washing with FACS buffer, cells were further incubated with 20 ml of phycoerythrin (PE)- conjugated streptavidin (Southern Biotechnology Associates). Ten thousand viable cells were analyzed with a FACScan flow cytometer (BD). Mean fluorescence intensity (MFI) was analyzed with WinMDi software.

Preparation of viral stock and whole-cell lysates from SARS CoV-infected cells. (A) Potential antigenic peptides predicted by EMBOSS:Antigenic. The scores are related to the immunogenicity of the peptides. (B) The same alignment is shown here. The shaded region showed significant homology and the “+” signs indicate homologous changes. The starting point corresponds to the N terminus of the S protein. (C) The consoids for S-I and S-II were optimized for usage in E. coli, and 18 oligonucleotides grouped with sticky overlap ends were synthesized and annealed together as nicked double-stranded DNA and ligase treated. The synthesized dsDNA was cloned into the expression vector pET100/D-TOPO with a His6 tag and an Ek recognition site at the N terminus (Invitrogen), and protein expression was induced with IPTG in BL21/ED5 host cells. The inclusion bodies containing S-I and S-II were dissolved in 8 M urea and refolded in 20 mM Tris buffer. (D) The purified, refolded soluble S-II was 2 mg/liter. Lanes: 1, molecular mass marker; 2, denatured S-II expressed in E. coli; 3, purified, refolded S-II.

Western blot analysis of whole-cell lysates of SARS CoV-infected Vero cells. (A) S-II and S-III were immunoprecipitated from the supernatant of infected Vero cells in 162-cm2 culture flasks (Invitrogen). In addition, the cDNA fragments encoding aa 145 to 480 (S-I) and 601 to 973 (S-III) of the SARS CoV S protein were obtained by reverse transcription-PCR with the RNA genome of SARS CoV (Toronto-2 isolate) as the template and cloned into the pET32a vector. All proteins were expressed in transformed BL21(DE3) host cells induced by isopropyl-β-D-thiogalactopyranoside (IPTG) for 4 h. The inclusion bodies containing the recombinant proteins were dissolved in 8 M urea and refolded in 20 mM Tris buffer. (B) The same antigenic peptides predicted by EMBOSS:Antigenic. The scores are related to the immunogenicity of the peptides. (C) The alignment is shown here. The shaded region showed significant homology and the “+” signs indicate homologous changes. The starting point corresponds to the N terminus of the S protein.
were analyzed on a PE-Scien (Concord, Ontario, Canada) API III triple-quadrupole mass spectrometer in the University of Alabama Comprehensive Cancer Center (P30 CA-13148). The molecular mass pattern of the nonreducing sample was the same as that of the reducing sample. The nonreducing ~600-kDa species could therefore only be interpreted as the trimeric complex of the ~180-kDa, monomeric S protein.

**Immunoprecipitation of SARS CoV with anti-S-II MAbs.** One milliliter of 10^8 PFU of the Toronto-2 virus was added to anti-S MAbs, which were directly conjugated to Sepharose 4B and incubated for 30 min at 4°C in a shaker. After washing, the immunoprecipitated viruses were dissolved in 100 μl of SDS-PAGE buffer. The dissolved proteins were separated by SDS–7% PAG and blotted. The S and N proteins were detected by Western blot analysis with HRP-conjugated anti-S and anti-N MAbs.

**Neutralizing activity of MAbs and antisera in SARS CoV-infected Vero cells.** Ten-fold-diluted antisera or MAbs were added to duplicate 24-well plates containing confluent monolayers of Vero cells in Iscove's modified Eagle medium—2% fetal bovine serum—2 mM l-glutamine—antibiotics. SARS HCoV (Toronto-2 isolate) was added to each well at a final concentration of 0.5 PFU/ml, and plates were incubated for 2 h at 37°C in 5% CO₂. Medium was removed from the wells, one set of plates was fixed with 80% acetone in PBS for immunostaining, and 0.1% SDS was added to the other plates for analysis by ELISA. Neutralizing activity was measured by plaque reduction. Equal amounts (1 μg/ml) of S-II (10, and 1 μg/100 μl) and SARS HCoV (10^3 PFU of Toronto-2 virus per 100 μl in DMEM) were mixed and incubated at 37°C in 5% CO₂ for 1 h. Two hundred microliters of the MAb-virus mixture were added to confluent monolayers of Vero cells in six-well plates in duplicate. Plates were incubated for 1 h at 37°C in 5% CO₂. Cells were overlaid with agar and incubated for 72 h at 37°C in 5% CO₂. Wells were fixed, overlays were removed, and cells were stained with crystal violet. Plaques were counted and recorded.

**Detection of SARS CoV N protein in infected Vero cells.** For sandwich ELISA, high-binding ELISA plates (Costar) were coated with two purified anti-SARS N protein MAbs, reactive with the N or C terminus of the N protein, at 4 μg/ml in PBS at 4°C overnight and blocked with 3% BSA–PBS at RT for 1 h. The whole-cell lysates from SARS CoV-infected Vero cells, prepared as described above, were serially diluted in 3% BSA–PBS (1:10; 1:100; and 1:1,000), 100 μl volumes of diluted lysates were added, and the mixtures were incubated at RT for 40 min. The captured N protein was detected by incubation with 1 μg of HRP-conjugated polyonal anti-SARS N protein antibody per ml at RT for another 40 min. The reaction was developed with TMB buffer, and the OD values were recorded with an ELISA plate reader (Bio-Rad) at wavelengths of 450 and 650 nm. A standard curve with the full-length recombinant N protein was generated, and the N protein concentration in the infected cells was calculated. For Western blot analysis, whole-cell lysates were prepared in the reducing SDS-PAGE sample buffer, subjected to SDS–10% PAGE, and transferred onto a nitrocellulose membrane. The blots were blocked with 5% milk–PBS and probed with 1 μg of HRP-conjugated anti-SARS N protein per ml at 4°C overnight. The reaction was developed with enhanced chemiluminescence buffer. For immunohistochromistry staining of SARS CoV-infected cells, SARS CoV-infected Vero cells were fixed in 24-well plates with acetone and air dried. The fixed cells were rehydrated with PBS and blocked with 20% goat serum PBS at RT for 40 min. Cells were then incubated with 0.2 μg of HRP-conjugated anti-SARS N MAb per ml at RT for 30 min, and the reaction was developed with DAB substrate buffer (Sigma). The staining was examined under an inverted fluorescence microscope and photographed at a magnification of ×400.

**Mapping of neutralizing epitopes with anti-S-II MAbs.** Six truncated S-II peptides were expressed in *E. coli* with the pET32a vector. Six peptides were truncated at the N or C terminus of S-II and made 20, 40, and 60 residues shorter, respectively. The purified peptides were used to coat an ELISA plate, which was incubated with each of the HRP-conjugated anti-S-II MAbs. OD values greater than 2.0 were judged positive, and those less than 0.1 were judged negative.

**RESULTS**

**Expression and characterization of S protein fragments.** Amino acid sequence alignment showed a low homology of the SARS CoV S protein to those of other CoVs. However, it is likely that the exposed epitopes and the receptor binding regions are located in the S protein corresponding to the S1 subunit on the basis of sequence analysis and modeling (11, 15, 17). With the EMBOSS:Antigenic program (9, 14), the top five predicted antigenic sites could be found in the S1 region (aa 1 to 690) of the SARS CoV S protein (Fig. 1A). A protein fragment of residues 145 to 480 (S-I) could present two peptides, and a protein fragment of residues 485 to 625 (S-II) could present another two peptides. Residues 4 to 11 are not considered because a short peptide may not form a stable conformation. Interestingly, S-II has partial homology to the identified receptor binding domain (residues 407 to 547) of the S protein of HCoV 229E (GenBank accession no. 13604338) (Fig. 1B). S-I has homology to the receptor binding N-terminal region of MHV (data not shown), but it did not bind the surface of Vero cells, as shown below. The codons in the coding region for the selected S-II fragment were optimized for usage in *E. coli* (13), and oligonucleotides grouped with sticky overlap ends were annealed together as nicked double-stranded DNA and ligated before cloning into the expression vector pET100/D-TOPO (Invitrogen). Protein expression was induced with IPTG, and S-II was expressed as an insoluble...
FIG. 3. Neutralizing activity of anti-S-II MAbs. Various concentrations of diluted MAbs were added to duplicate 24-well plates containing confluent monolayers of Vero76 cells in Iscove’s modified Eagle medium–2% fetal bovine serum–2 mM l-glutamine–antibiotics. SARS CoV (Toronto-2 isolate) was added to each well at a final concentration of 0.5 PFU/ml, and plates were incubated for 72 h at 37°C in 5% CO2. Medium was removed from the wells, one set of plates was fixed with 80% acetone in PBS for immunostaining, and 0.1% SDS was added to the other set of plates for analysis by ELISA. (A) Quantitative measurement of the SARS CoV N protein for neutralizing activity. A quantitative ELISA of SARS CoV N protein was developed for measurement of viral infection (T.Z. et al., submitted). Briefly, an ELISA plate was coated with two MAbs against the N and C termini of the SARS CoV N protein. Whole-cell lysates (0.1% SDS) of infected cells were diluted 1:100 and 1:1,000 in 3% BSA–PBS and incubated in a MAb-coated plate. The captured N protein was then detected with HRP-conjugated polyconal goat anti-N antibody. The N protein content was determined with the full-length of recombinant N protein as the standard. IgG, immunoglobulin G. (B) Western blot analysis of the N protein in MAb-treated Vero cells infected with SARS CoV. Five microliters of whole-cell lysate was separated by SDS–10% PAGE and blotted. The N protein was probed with an HRP-conjugated MAb against N protein. (C) Immunohistochemistry detection of SARS CoV-infected cells. Acetone-fixed cells were stained with an HRP-conjugated anti-N MAb and revealed by DAB substrate buffer. Photos were
protein in \textit{E. coli}. The inclusion bodies were dissolved in 8 M Urea, refolded, and purified by Ni affinity chromatography (Fig. 1C). To determine whether the designed S protein fragments contained any Vero cell binding activities, the purified S-I and refolded S-II fragments were biotinylated and used as a probe for specific binding to the surface of Vero E6 cells. Flow cytometry analysis demonstrates that S-II, but not a control protein, bound to the surface of Vero E6 cells (Fig. 1D). There was a dose-dependent increase in the staining intensity of bound S-II but not the control protein, as shown by the increasing MFI (Fig. 1E). S-I and S-III (aa 601 to 973) were also expressed and tested for the ability to bind to Vero E6 cells. There was no significant binding of the other two fragments (Fig. 1D). These results indicate that the designated S-II peptide could be involved in specific binding to the Vero cell surface, perhaps the receptor(s). Therefore, S-II was selected for further studies for its potential to generate neutralizing antibodies.

**Characterization of MAbs against S-II.** BALB/c mice were immunized with the refolded S-II fragment in Freund’s com-

<table>
<thead>
<tr>
<th>S peptides</th>
<th>S26</th>
<th>S34</th>
<th>S78</th>
<th>S84</th>
</tr>
</thead>
<tbody>
<tr>
<td>S488-627</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>S508-627</td>
<td>+</td>
<td>+</td>
<td></td>
<td>+</td>
</tr>
<tr>
<td>S528-627</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>S548-627</td>
<td></td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>S488-607</td>
<td>-</td>
<td>+</td>
<td></td>
<td>+</td>
</tr>
<tr>
<td>S488-587</td>
<td>-</td>
<td></td>
<td></td>
<td>+</td>
</tr>
<tr>
<td>S488-567</td>
<td>-</td>
<td></td>
<td></td>
<td>+</td>
</tr>
</tbody>
</table>

The values at the top are the concentrations of the MAbs used for neutralization. (D) Neutralizing epitope mapping of anti-S-II MAbs. A series of the truncated S-II peptides were expressed in \textit{E. coli} with a His, tag at the N terminus. The truncated peptides were used to coat ELISA plates, which were incubated with 1 μg of HRP-conjugated anti-S-II MAbs per ml. (E) Location of the neutralizing epitopes relative to the S-I, S-II, and S-III fragments within the S protein.
complete adjuvant and boosted with S-II in PBS four times. Lymphocytes from the draining lymph nodes were fused with NS1 myeloma cells. Four hybridoma clones producing high-affinity anti-S-II antibody, S26, S34, S78, and S84, were selected. HRP-conjugated S34 and S78 reacted with acetone-fixed SARS CoV (Toronto-2 strain)-infected Vero cells but not with noninfected Vero cells or cells infected with two common HCoVs, 229E and OC43 (Fig. 2A). All anti-S-II MAbs, but not a control MAb, were able to capture the native form of the S protein from whole-cell lysates of SARS CoV-infected Vero cells. In an ELISA format with the MAbs used individually as a capture antibody and an HRP-conjugated polyclonal goat anti-S-II antibody used as the detecting antibody, the content of the S protein in SARS CoV-infected Vero cells could be quantitatively measured. At 72 h after infection, the content of the S protein in whole-cell lysates was well correlated with the number of viral PFU (Fig. 2B). Neither ELISAs with the control capture antibody nor ELISAs with cell lysates from noninfected Vero cells showed a significant reaction (data not shown). In a Western blot paradigm, the whole-cell lysate of SARS CoV-infected Vero cells was prepared under both reducing and nonreducing conditions, electrophoresed by SDS-PAGE, and probed with each of the four MAbs against S-II.

All of the antibodies recognized the S protein prepared under both reducing and nonreducing conditions. Under reducing conditions, the antibodies recognized an ~180-kDa protein as predicted (Fig. 2C, lane 1). However, under nonreducing conditions, an ~600-kDa protein predominated (Fig. 2C, lane 2). The reactivity of the MAb was specific for SARS CoV, as the lysates of the control Vero cells did not show any reaction under either reducing or nonreducing conditions (Fig. 2C, lanes 3 and 4). The S protein in the whole-cell lysate of infected Vero cells could be immunoprecipitated with MAbs against S-II, and SDS-PAGE analysis of the affinity-purified S protein demonstrated that the ~600-kDa protein was homotrimERIC, as identified by mass spectrometry (see Materials and Methods), indicating that the SARS S protein might exist as a trimer in its native form. Conjugated to Sepharose 4B, each of the anti-S-II MAbs was able to immunoprecipitate viral particles in the supernatants from SARS CoV-infected Vero cells. After immunoprecipitation of viral particles, both the S and N proteins could be detected in a Western blot assay with HRP-conjugated anti-S and anti-N MAbs (Fig. 2D). These results indicate that MAbs raised against the designated S-II peptide specifically recognize the native S protein of SARS CoV.

The four anti-S-II MAbs were able to inhibit the binding of S-II to the Vero E6 cell surface in a dose-dependent fashion (Fig. 2E). Among the four antibodies, S34 and S84 showed more blocking activity than either S26 or S78. The blocking activity of MAbs was further confirmed in a competitive ELISA in which the S-II affinity-purified cell membrane proteins of Vero E6 cells were biotinylated and incubated with the plate-coated S-II peptide in the presence of various concentrations of MAbs. A similar inhibition of binding of S-II to the Vero cell surface was observed (Fig. 2F). These results indicate that anti-S-II MAbs are capable of blocking the surface-binding activities of S-II.

In vitro antiviral activity of anti-S-II MAbs. If the S-II region of the S protein is involved in the attachment of the SARS CoV to its host cells, we would expect the blocking activity of MAbs against S-II to have a parallel neutralizing activity. To test this hypothesis, we examined the neutralizing activity of MAbs by assessing the inhibition of productive SARS CoV infection of Vero E6 cells in culture. As the expression of the N protein in SARS CoV-infected cells is a sensitive marker of infection, we have developed a sensitive and high-throughput ELISA for quantitative measurement of SARS CoV N protein (T.Z. et al., submitted). The antiviral activity of each MAb was evaluated by measuring the N protein with a quantitative ELISA, Western blotting, and in situ immunohistochemistry. By ELISA, control immunoglobulin G had no effect on the infection of Vero cells compared to that of cells incubated with virus alone. In contrast, all four anti-S-II MAbs inhibited SARS CoV infection (Fig. 3A). Two MAbs, S34 and S84, at 10 μg/ml completely inhibited viral infection at a multiplicity of infection of 0.5 and showed no detectable N protein comparable to that in noninfected control cells. The other two MAbs produced a >80% reduction in N protein production at 100 μg/ml. Western blot analysis of whole-cell lysates confirmed the absence of detectable viral protein in cell cultures incubated with 10 μg of S34 and S84 per ml (Fig. 3B). In situ immunohistochemistry staining demonstrated that there was no significant staining of SARS CoV N protein in cells incu-

---

TABLE 1. Neutralization of MAbs by plaque assay

<table>
<thead>
<tr>
<th>MAb</th>
<th>Activity (PFU) at indicated concn (μg/ml):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
</tr>
<tr>
<td>S26</td>
<td>54</td>
</tr>
<tr>
<td>S34</td>
<td>300</td>
</tr>
<tr>
<td>S84</td>
<td>300</td>
</tr>
<tr>
<td>S78</td>
<td>69</td>
</tr>
<tr>
<td>Positive control</td>
<td>320</td>
</tr>
</tbody>
</table>

Elizabeth S. Zou ET AL. J. VIROL.

FIG. 4. S-II elicits a protective antibody response against SARS CoV. Six- to 8-week-old female BALB/c mice were subcutaneously immunized with 100 μg of S-II in Freund’s complete adjuvant and boosted twice with S-II in PBS weekly. Serum samples were collected at the indicated time points after primary immunization. (A) Serum levels of anti-S-II antibody were measured by indirect ELISA with an anti-S-II MAb as the standard. IgG, immunoglobulin G. (B) The 10-fold-diluted sera were added to Vero E6 cell cultures 1 h prior to infection of each well with 0.5 PFU of SARS CoV per ml. The neutralizing activity of antisera was determined by quantitative measurement of N protein by ELISA as described above. The results are presented as the mean ± the standard deviation of two pools of six mice at each time point.
bated with antibodies at concentrations of \( \geq 10 \, \mu g/ml \). The neutralizing activity of some MAbs was also confirmed by the plaque reduction assay (1). The four antibodies showed similar activities at 50 \( \mu g/ml \) when a total of 10\(^3\) PFU of virus per well was added to a six-well plate.

To map the S-II epitopes recognized by these neutralizing antibodies, we truncated the S-II peptide at both the N and C termini and expressed a panel of shorter peptides in \( E. coli \). The profile of MAbs binding to these truncated peptides (Fig. 3D) indicates that S26 and S78 recognize an epitope within the 20 aa at the C terminus (aa 607 to 627), whereas S34 and S84 recognize an epitope (aa 548 to 567) in the middle of the S-II peptide immediately adjacent to a region significantly homologous to the receptor binding domain of HCoV 229E (Fig. 1B and 3E). Therefore, although S34 and S84 had the strongest neutralizing activity, there are at least two epitopes in the S protein that could elicit protective immunity against SARS CoV infection.

**S-II elicits a protective antibody response.** BALB/c mice were subcutaneously immunized with 100 \( \mu g \) of S-II in Freund's complete adjuvant and boosted twice at weekly intervals. The titer of specific anti-S-II reactivity and of neutralizing activity for sera obtained at 2, 4, 8, and 8 weeks after initial immunization showed a time-dependent increase (Fig. 4A and B). Compared to preimmune sera, significant neutralizing activity was observed as early as 2 weeks after primary immunization although the titers were low. However, high titers and maximal protection were observed after 4 weeks and were maintained at 8 weeks. Thus, S-II, a small part of the S protein of SARS CoV, is sufficient to elicit an endogenous, protective antiviral antibody response.

**DISCUSSION**

Selecting from regions of the S protein of SARS CoV that are predicted to potentially present antigenic determinants, a small region (S-II) comprising residues 485 to 625 was expressed as a recombinant protein in \( E. coli \). After proper refolding, the solubilized S-II fragment was shown to specifically bind the surface of Vero cells by FACS analysis. This suggests that antibodies against this region could give rise to neutralizing activities. A panel of MAbs was raised with the recombinant S-II protein. A series of tests showed that the MAbs could recognize the native S protein, block the attachment of S-II to Vero cells, and neutralize SARS CoV infection in cell culture.

Virus entry involves attachment of the S1 region to the host receptor and exposure of the fusion peptide that results from the conformational change induced by the interaction of the S1 region with the receptor. However, studies with HCoV 229E, MHV, and TGEV further defined polypeptide regions that can bind the host receptor. A receptor binding domain of HCoV 229E was identified as aa 407 to 547 (3), and that of TGEV was identified as aa 506 to 655 (7, 18), which corresponds to aa 279 to 417 by amino acid sequence alignment (3). A receptor binding domain was mapped to the N-terminal 330 aa of MHV (10). These observations suggest that a defined receptor binding domain could be located in various regions of the S protein, depending on the host receptor. The entire S1 region may be required for the full function while a local region is responsible for attachment to the receptor. S-II was shown to bind the host cell surface in this study, which is most closely related to the receptor binding domain identified for HCoV 229E with moderate homology in the local region. This is consistent with the studies of Wong et al. (19) and Xiao et al. (20) in which the more C-terminal region of the SARS CoV S protein was shown to bind the isolated receptor angiotensin-converting enzyme 2. The minimum overlapping region between S-II and other angiotensin-converting enzyme 2 binding fragments is aa 485 to 510.

With the MAbs generated with S-II, we have identified the predicted 180-kDa S protein of SARS CoV. These MAbs also recognize a putatively trimmed form of the S protein, which may represent its native form, and recognition of the trimmed form may be important for antibody neutralizing activity. Our data indicate that at least one binding-related region of the SARS CoV S protein is located within amino acid residues 485 to 625. Epitope mapping demonstrates that two exposed regions, aa 607 to 627 and 548 to 567, are located in this peptide, which is separated from the suggested minimum binding region. Development of an effective antiviral antibody response in mice immunized with S-II suggests that S-II might be an appropriate target in vaccine development for generation of protective humoral immunity in humans. Moreover, identification of S-II as a critical antigenic determinant within the S protein will be helpful in the development of an immunoassay to evaluate effective, protective antibody responses in patients during SARS CoV infection. The in vitro antiviral activity of anti-S-II MAbs suggests strategies for the development of therapeutic neutralizing antibodies effective for passive immunization in the prevention and perhaps treatment of SARS CoV infection. In addition, paired MAbs specific for the SARS CoV S protein and able to immunoprecipitate intact viral particles will enable quantitative immunoassays for measurement of viral particles in specimens from SARS patients.

**ACKNOWLEDGMENTS**

T.Z. is supported by a research grant from Sankyo Co., Ltd., Tokyo, Japan. We thank William J. Koopman for critical comments.

**REFERENCES**


